David Schwartz

David Schwartz, partner and leader of the corporate and business transactions practice in the Princeton office, advises a broad range of clients in the life sciences, healthcare, and technology industries. He currently holds leadership positions in the firm’s capital markets public company practice and biotech and beyond industry team.

His practice focuses on capital markets transactions, SEC reporting and compliance, mergers and acquisitions (M&A), deSPACs and other strategic transactions, private equity and venture capital transactions, and corporate governance matters. He works with clients of all sizes, including startups and growth businesses, publicly held middle-market companies, venture capital firms, strategic investors, and underwriters.

He regularly advises clients in connection with initial public offerings (IPOs), follow-on offerings, at-the-market offerings (ATMs), private investments in public equity (PIPEs), and registered direct offerings, in addition to venture capital, private equity, M&A, going-private, and other strategic transactions. He also acts as counsel for both public and private companies at various stages of development, providing general corporate representation and advice to boards of directors and management concerning corporate governance matters.

He previously practiced as an associate at Morgan Lewis and returned to the firm in 2019 after working as a partner at another global law firm and helping to establish its New Jersey office. There, he served as a member of its national leadership group of the US emerging growth and venture capital practice.

He is a frequent panelist on topics involving venture capital, public offerings, corporate governance, and M&A transactions. While attending law school, he worked in the Enforcement Division of the US Securities and Exchange Commission’s Philadelphia regional office.

To learn more about David and his experience, please go to: https://www.morganlewis.com/bios/davidschwartz